Phase II trial of cis‐dichlorodiammineplatinum (II) in advanced malignant lymphoma: A study of the cancer and acute leukemia group B

Publisher Website
Google Scholar
Abstract
In a cooperative study of the Cancer and Acute Leukemia Group B, 27 evaluable patients with advanced malignant lymphomas were treated with 70 mg/m2 of cisdichlorodiammineplatinum(II) (cis-platinum) once every 3 wk. All patients had received extensive prior therapy. Partial remission was obtained in 2 of 8 patients (25%) with Hodgkin''s disease, for 6 and 40 wk, and in 5 of 19 (26%) patients with non-Hodgkin''s lymphoma, for a median duration of 6 wk. The major toxic effects were profuse vomiting and, to a lesser degree, myelosuppression. Nephrotoxicity was easily controlled. Cis-platinum is an active agent in lymphoma and should merit incorporation into combination therapy for recently diagnosed disease.